Autor: "Colombel, Jean-Frédéric" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.
Autorzy:: Philip G; Global Clinical Development, Merck & Co., Inc., Kenilworth, NJ, USA.
Cornillie F; Global Medical Affairs, MSD International, Kriens-Luzern, Switzerland.
Adedokun JO; Immunology, Janssen Research & Development, LLC, Spring House, PA, USA.
Melsheimer R; Medical Affairs, Janssen Biologics BV, Leiden, The Netherlands.
Rutgeerts P; Department of Endoscopy, University Hospital Gasthuisberg, Leuven, Belgium.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Marano C; Immunology, Janssen Research & Development, LLC, Spring House, PA, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2019 Sep 27; Vol. 13 (10), pp. 1257-1264.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Antibodies, Monoclonal/*administration & dosage
Colitis, Ulcerative/*drug therapy
Gastrointestinal Agents/*administration & dosage
Antibodies, Monoclonal/blood ; Antibodies, Monoclonal/pharmacokinetics ; Antibodies, Monoclonal/therapeutic use ; C-Reactive Protein/analysis ; Feces/chemistry ; Gastrointestinal Agents/blood ; Gastrointestinal Agents/pharmacology ; Gastrointestinal Agents/therapeutic use ; Humans ; Leukocyte L1 Antigen Complex/analysis ; Remission Induction/methods ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study.
Autorzy:: Sandborn WJ; Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, CA, USA.
Rutgeerts P; Department of Gastroenterology, Catholic University Leuven, Belgium.
Colombel JF; Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ghosh S; Division of Gastroenterology, University of Calgary, Calgary, AB, Canada.
Petryka R; NZOZ Vivamed, Zespól Lekarzy Specjalistów, Warszawa, Poland.
Sands BE; Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mitra P; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Luo A; Bristol-Myers Squibb, Lawrenceville, NJ, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2017 Jul 01; Vol. 11 (7), pp. 811-819.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms:: Antibodies, Monoclonal/*therapeutic use
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Adult ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Colonoscopy ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/adverse effects ; Humans ; Male ; Middle Aged ; Remission Induction ; Severity of Illness Index ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.
Autorzy:: Sandborn WJ; Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, CA, USA .
Colombel JF; Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ghosh S; Department of Medicine, University of Calgary, Calgary, AB, Canada.
Sands BE; Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Dryden G; Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville School of Medicine, Louisville, KY, USA.
Hébuterne X; Faculté de Médecine, Université de Nice-Sophia Antipolis, Hôpital de l'Archet, Nice, France.
Leong RW; Concord Hospital, Gastroenterology and Liver Services, University of New South Wales, Sydney, Australia.
Bressler B; Division of Gastroenterology, St Paul's Hospital, Vancouver, BC, Canada.
Ullman T; Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Lakatos PL; 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and McMaster University, Department of Internal Medicine, Hamilton, ON, Canada.
Xu LA; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Luo A; Formerly of Bristol-Myers Squibb, Lawrenceville, NJ, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2016 Apr; Vol. 10 (4), pp. 418-28. Date of Electronic Publication: 2015 Dec 30.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibodies, Monoclonal/*therapeutic use
Chemokine CXCL10/*antagonists & inhibitors
Colitis, Ulcerative/*drug therapy
Gastrointestinal Agents/*therapeutic use
Adolescent ; Adult ; Aged ; Female ; Gastrointestinal Agents/administration & dosage ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Remission Induction ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Colombel, Jean-Frédéric"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Język